QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 27, 2018

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
DRUG

NANT-008

Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)

DRUG

Fluorouracil Injectable Product

5-fluoro-2,4 (1H,3H)-pyrimidinedione.

DRUG

Avastin Injectable Product

Recombinant humanized monoclonal IgG1 antibody

DRUG

Leucovorin Calcium Injection

Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).

DRUG

Eloxatin Injectable Product

cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.

Trial Locations (1)

90245

Chan Soon-Shiong Institutes for Medicine, El Segundo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NantPharma, LLC

INDUSTRY